A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2019
Price : $35 *
At a glance
- Drugs JAB-3068 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jacobio Pharmaceuticals
- 15 May 2018 Planned End Date changed from 30 Apr 2020 to 1 Apr 2020.
- 15 May 2018 Planned primary completion date changed from 30 Nov 2019 to 1 Nov 2019.
- 15 May 2018 Status changed from not yet recruiting to recruiting.